Bryan Garnier - Luxury Fashion: Fashion: Omicron variant could spoil the Christmas party

Report

Bryan Garnier

Cedric Rossi

Luxury & Fashion: Fashion: Omicron variant could spoil the Christmas party

Luxury & Fashion
Fashion: Omicron variant could spoil the Christmas party

Sequential improvements across Continental Europe…
… but Omicron could dash hopes of a return to normal in Q4
ITX less affected than H&M by external factors…
… hence we continue to prefer ITX in the near-term

02/12/2021 4 EN

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Cedric Rossi

Other Reports from Bryan Garnier

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Avantium: FDCA offtake agreement with PLIXXENT

This morning Avantium announced it has signed a five-year conditional offtake agreement with PLIXXENT, an independent polyurethane systems manufacturing house answering various industries, from construction to footwear, energy or automotive. This confirms FDCA as a versatile monomer and extends its

9h / 36m 9h / 36m 1 EN

Cédric Rossi

Cédric Rossi

BIC: slow improvement amid US macro volatility

Ahead of H1 2025 results due on 30th July, we expect a slow sequential improvement at the top-line level with a flattish LFL sales performance in Q2 (-0.4%e vs. -7% in Q1) thanks to a gradual resumption in wholesale orders in North America. Obviously H1 margins are set to be pressurised by negative

9h / 42m 9h / 42m 1 EN

Damien Choplain ... (+2)

Damien Choplain
Oscar Haffen Lamm

Initiation of coverage: The 'Clever' way to tackle MDS

Faron Pharmaceuticals is a Finnish biotech developing bexmarilimab (BEX), an immunotherapy in late stage development for the treatment of a rare type of hematologic cancer, high-risk myelodysplastic syndrome (HR-MDS). Encouraging phase 2 data supports a phase 3 trial starting H1 2026, targeting bot

July 7, 2025 July 7, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Luxury & Fashion: Fashion: Omicron variant could spoil the Christmas party

Avantium: FDCA offtake agreement with PLIXXENT

BIC: slow improvement amid US macro volatility

Initiation of coverage: The 'Clever' way to tackle MDS

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe